MX2018014679A - Proteinas de fusion para oftalmologia con retencion ocular aumentada. - Google Patents
Proteinas de fusion para oftalmologia con retencion ocular aumentada.Info
- Publication number
- MX2018014679A MX2018014679A MX2018014679A MX2018014679A MX2018014679A MX 2018014679 A MX2018014679 A MX 2018014679A MX 2018014679 A MX2018014679 A MX 2018014679A MX 2018014679 A MX2018014679 A MX 2018014679A MX 2018014679 A MX2018014679 A MX 2018014679A
- Authority
- MX
- Mexico
- Prior art keywords
- binding site
- site specifically
- binding
- collagen
- compound
- Prior art date
Links
- 230000014759 maintenance of location Effects 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 4
- 210000002744 extracellular matrix Anatomy 0.000 abstract 4
- 102000008186 Collagen Human genes 0.000 abstract 3
- 108010035532 Collagen Proteins 0.000 abstract 3
- 239000011230 binding agent Substances 0.000 abstract 3
- 229920001436 collagen Polymers 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 210000004127 vitreous body Anatomy 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La combinación de un primer sitio de unión que se une específicamente a una diana asociada con una enfermedad ocular y un segundo sitio de unión que se une específicamente a una diana que influye en la retención en el ojo de un enlazante multiespecífico proporciona una retención intravítrea mejorada en comparación con un enlazante monospecífico. El segundo sitio de unión se une específicamente a un compuesto/moléculas encontradas en la matriz extracelular (ECM) del humor vítreo/retina. Este compuesto de la matriz extracelular tiene que estar presente en cantidades que permitan una carga/dosis suficiente del fármaco que se va a unir. Se ha encontrado que el colágeno, especialmente el colágeno de tipo II, es un compuesto adecuado en la ECM en el humor vítreo para este propósito. De este modo, se describe en este documento un enlazante multiespecífico que comprende un primer sitio de unión que se une específicamente a una diana ocular terapéutica y un segundo sitio de unión que se. une específicamente al colágeno de tipo II.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16173166 | 2016-06-06 | ||
PCT/EP2017/063506 WO2017211731A1 (en) | 2016-06-06 | 2017-06-02 | Fusion proteins for ophthalmology with increased eye retention |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018014679A true MX2018014679A (es) | 2019-04-29 |
Family
ID=56132771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018014679A MX2018014679A (es) | 2016-06-06 | 2017-06-02 | Proteinas de fusion para oftalmologia con retencion ocular aumentada. |
Country Status (12)
Country | Link |
---|---|
US (2) | US10836816B2 (es) |
EP (1) | EP3464345A1 (es) |
JP (1) | JP6921943B2 (es) |
KR (1) | KR102187751B1 (es) |
CN (1) | CN109311964B (es) |
AR (1) | AR108681A1 (es) |
AU (1) | AU2017276604B2 (es) |
BR (1) | BR112018074771A2 (es) |
CA (1) | CA3025995C (es) |
IL (1) | IL262996B2 (es) |
MX (1) | MX2018014679A (es) |
WO (1) | WO2017211731A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL262996B2 (en) | 2016-06-06 | 2024-03-01 | Hoffmann La Roche | Fusion proteins for ophthalmology with increased grip in the eye |
WO2022223140A1 (en) * | 2021-04-23 | 2022-10-27 | Navigo Proteins Gmbh | Fusion proteins with specifity for type ii collagen and vegf-a for the treatment of eye diseases |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
IL136544A0 (en) | 1997-12-05 | 2001-06-14 | Scripps Research Inst | Humanization of murine antibody |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US7365167B2 (en) * | 2001-11-26 | 2008-04-29 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック, インコーポレイテッド | 合成抗体ファージライブラリー |
CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
GB0708585D0 (en) | 2007-05-03 | 2007-06-13 | Queen Mary & Westfield College | Novel antibody and use in diagnosis and therapy of arthropathies |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
US8906649B2 (en) * | 2010-09-27 | 2014-12-09 | Janssen Biotech, Inc. | Antibodies binding human collagen II |
CA2812389C (en) * | 2010-09-27 | 2019-12-31 | John Kehoe | Antibodies binding human collagen ii |
TW201427989A (zh) | 2012-12-18 | 2014-07-16 | Novartis Ag | 長效性蛋白質之組合物及方法 |
AU2015206515B2 (en) * | 2014-01-15 | 2019-12-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cartilage targeting agents and their use |
SI3189081T1 (sl) | 2014-09-05 | 2020-07-31 | Janssen Pharmaceutica Nv | Sredstva, ki se vežejo na CD123 in njihove uporabe |
IL262996B2 (en) | 2016-06-06 | 2024-03-01 | Hoffmann La Roche | Fusion proteins for ophthalmology with increased grip in the eye |
JP6983824B2 (ja) * | 2016-07-04 | 2021-12-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 新規抗体フォーマット |
-
2017
- 2017-06-02 IL IL262996A patent/IL262996B2/en unknown
- 2017-06-02 WO PCT/EP2017/063506 patent/WO2017211731A1/en unknown
- 2017-06-02 EP EP17728816.4A patent/EP3464345A1/en active Pending
- 2017-06-02 AU AU2017276604A patent/AU2017276604B2/en active Active
- 2017-06-02 MX MX2018014679A patent/MX2018014679A/es unknown
- 2017-06-02 CA CA3025995A patent/CA3025995C/en active Active
- 2017-06-02 JP JP2019516078A patent/JP6921943B2/ja active Active
- 2017-06-02 BR BR112018074771-8A patent/BR112018074771A2/pt unknown
- 2017-06-02 CN CN201780034951.2A patent/CN109311964B/zh active Active
- 2017-06-02 KR KR1020197000139A patent/KR102187751B1/ko active IP Right Grant
- 2017-06-05 AR ARP170101528A patent/AR108681A1/es unknown
-
2018
- 2018-12-04 US US16/209,575 patent/US10836816B2/en active Active
-
2020
- 2020-10-08 US US17/066,215 patent/US11673942B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11673942B2 (en) | 2023-06-13 |
IL262996B2 (en) | 2024-03-01 |
US20190225676A1 (en) | 2019-07-25 |
CN109311964A (zh) | 2019-02-05 |
IL262996A (en) | 2018-12-31 |
CA3025995C (en) | 2023-08-08 |
EP3464345A1 (en) | 2019-04-10 |
KR20190015481A (ko) | 2019-02-13 |
CA3025995A1 (en) | 2017-12-14 |
US10836816B2 (en) | 2020-11-17 |
WO2017211731A1 (en) | 2017-12-14 |
AU2017276604B2 (en) | 2020-02-27 |
IL262996B1 (en) | 2023-11-01 |
KR102187751B1 (ko) | 2020-12-08 |
BR112018074771A2 (pt) | 2019-03-06 |
AR108681A1 (es) | 2018-09-12 |
JP2019524870A (ja) | 2019-09-05 |
JP6921943B2 (ja) | 2021-08-18 |
AU2017276604A1 (en) | 2018-11-29 |
US20210024624A1 (en) | 2021-01-28 |
CN109311964B (zh) | 2022-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500231A1 (en) | Interleukin-21 muteins and methods of treatment | |
EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
MY197845A (en) | Pharmaceutical composition | |
CL2015002485A1 (es) | Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares | |
BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
EA201591176A1 (ru) | Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном | |
BRPI0613401B8 (pt) | composição oftálmica compreendendo derivados de glicocorticoides que penetram seletivamente nos tecidos do segmento posterior | |
EA201991207A1 (ru) | Новые агонисты tnfr и их применение | |
BR112017020948A2 (pt) | composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão | |
MX2021002380A (es) | Conjugados de isoquinolina-esteroide y usos de los mismos. | |
EP4268843A3 (en) | Improved il-6 antibodies | |
MX2019001877A (es) | Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas. | |
WO2013058838A3 (en) | Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer | |
MX2019001021A (es) | Formulaciones de liposomas. | |
AU2019206958A1 (en) | PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
MY176525A (en) | Therapeutic agent for ocular disease or prophylactic agent for ocular disease | |
EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
BR112015027399A2 (pt) | ANTICORPOS ANTI-IGF-1R COM LIGAÇÃO DE FcRn ABOLIDA E SEU USO NO TRATAMENTO DE ENFERMIDADES VASCULARES OCULARES | |
MX2018014679A (es) | Proteinas de fusion para oftalmologia con retencion ocular aumentada. | |
MX355770B (es) | Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico. | |
IL287758A (en) | Anti-sema3a antibodies and their use for the treatment of eyes or eye diseases | |
EA202091478A1 (ru) | Антитела | |
EA202091974A1 (ru) | Связывающие bcma антитела и их применение | |
EP3976017A4 (en) | PHARMACOLOGICAL SUBSTANCES FOR THE TREATMENT OF PROTEIN AGGREGATION DISEASES OF THE EYE | |
WO2014161004A3 (en) | Compositions and methods for the delivery of drugs to the ocular surface by contact lenses |